ARN-509: a novel anti-androgen for prostate cancer treatment

Continued reliance on the androgen receptor (AR) is now understood as a core mechanism in castration-resistant prostate cancer (CRPC), the most advanced form of this disease. While established and novel AR-pathway targeting agents display clinical efficacy in metastatic CRPC, dose-limiting side effe...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Clegg, Nicola J., Wongvipat, John, Joseph, Jim, Tran, Chris, Ouk, Samedy, Dilhas, Anna, Chen, Yu, Grillot, Kate, Bischoff, Eric D., Cai, Ling, Aparicio, Anna, Dorow, Steven, Arora, Vivek, Shao, Gang, Qian, Jing, Zhao, Hong, Yang, Guangbin, Cao, Chunyan, Sensintaffar, John, Wasielewska, Teresa, Herbert, Mark R., Bonnefous, Celine, Darimont, Beatrice, Scher, Howard I., Smith-Jones, Peter, Klang, Mark, Smith, Nicholas D., De Stanchina, Elisa, Wu, Nian, Ouerfelli, Ouathek, Rix, Peter J., Heyman, Richard A., Jung, Michael E., Sawyers, Charles L., Hager, Jeffrey H.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3306502/
https://ncbi.nlm.nih.gov/pubmed/22266222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-3948
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky